All In Biotech

Drug Trial Radar · NCT03997968

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

169

Actual

Start

Oct 9, 2019

Primary completion

Nov 30, 2024

Study completion Dec 20, 2024

Sponsor

Lead sponsor
Cyteir Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Conditions

  • Malignancy
  • Non-hodgkin Lymphoma
  • Multiple Myeloma
  • Breast Cancer
  • Ovarian Cancer
  • Soft Tissue Sarcoma
  • Head and Neck Cancer
  • DLBCL
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Pancreatic Cancer
  • CLL
  • Small Cell Lung Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Triple Negative Breast Cancer

Interventions

  • CYT-0851Drug

    Part A and B: Daily oral doses of CYT-0851 for 28 day cycles

  • CYT-0851 in combination with gemcitabineDrug

    Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine

  • CYT-0851 in combination with capecitabineDrug

    Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine

  • CYT-0851 in combination with rituximab and bendamustineDrug

    Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence of dose limiting toxicityTime frame: 28 Days
  2. Part B: Objective response rateTime frame: 24 Weeks
  3. Part C: Incidence of dose limiting toxicityTime frame: 28 Days
  4. Part D: Incidence of dose limiting toxicityTime frame: 28 Days
  5. Part E: Incidence of dose limiting toxicityTime frame: 21 Days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Stanford Comprehensive Cancer Center

    Stanford, California

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • Florida Cancer Specialists and Research Institute

    Sarasota, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • John Theurer Cancer Center at HUMC

    Hackensack, New Jersey

  • NYU Langone Health

    New York, New York

  • Oklahoma University-Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Washington Seattle Cancer Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.